EICHORCondition: Diffuse Large B-Cell Lymphoma · Sponsor: Hoffmann-La Roche
Interested? Contact the study team ↓
This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
This description comes directly from the study's public registry record.
Reference Study ID Number: ML45172 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. and Canada) · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Histologically confirmed R/R DLBCL after one line of systemic therapy * Will be treated with Glofit-based regimen (known as being recommended and having the intention to be treated with Glofitamab at the time of signing ICF) or have initiated Glofit-based regimen treatment within three months (90 days) prior to enrollment Exclusion Criteria: * Participants who currently participate in or plan to participate in any interventional clinical trial
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Cancer Hospital Chinese Academy of Medical Sciences. | Langfang, Hebei, China | Recruiting |
| Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center | Tianjin, Tianjin Municipality, China | Recruiting |
| Peking University People's Hospital | Beijing, China | Recruiting |
| Peking University Third Hospital | Beijing, China | Recruiting |
| The First Bethune Hospital of Jilin University | Changchun, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, China | Recruiting |
| Guangdong Provincial People's Hospital | Guangzhou, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, China | Recruiting |
| Shandong Cancer Hospital | Jinan, China | Recruiting |
| The Second Affiliated Hospital of Nanchang University | Nanchang, China | Recruiting |
| The First Affiliated Hospital of Ningbo University | Ningbo, China | Recruiting |
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine | Shanghai, China | Recruiting |
+ 9 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07200375